Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P080020/S056

Gel-One

Seikagaku Corp. · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONP080020/S056

What did the FDA approve?

FDA recorded an approval decision on 2026-09-04 for PMA supplement P080020/S056, associated with Gel-One (Seikagaku Corp.). The supplement was filed under the 135 Review Track for 30-Day Notice with a recorded reason of Process Change - Manufacturer/Sterilizer/Packager/Supplier. The device category is listed as acid, hyaluronic, intraarticular, with orthopedic specialty and product code MOZ.

The recorded scope is limited to manufacturing: replacing one of two existing isolators used for sterility testing of Gel-One with a new isolator that has an integrated hydrogen peroxide decontamination system. This is a supplement-level decision about that equipment change, not a new approval of the Gel-One device or its clinical use. The source record does not include the supplement documents, so the review basis and any conditions tied to the isolator change remain unknown.

FDA approval order statement

Approval to replace one of two existing isolators used for sterility testing of Gel-One with a new isolator equipped with an integrated hydrogen peroxide decontamination system.
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Orthopedic
Decision date
Sep 4, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P080020/S056
Regulatory pathway
PMA supplement
Product code
MOZ
Decision code
APPR
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

For the original device and its historical approval scope, see PMA P080020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P080020/S056 received

    Application receipt date recorded by FDA.

  2. P080020/S056 · FDA decision

    135 Review Track For 30-Day Notice

Timeline entries are records held by MedtechLedger for P080020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P080020

Product / regulatory recordCompanyPathwayDecision dateSource
GEL-ONEP080020
Seikagaku Corp.PMA approvalMar 22, 2011FDA

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
SUPARTZ FXP980044/S067
Seikagaku Corp.PMA supplementSep 4, 2026FDA
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA
Ferring Pharmaceuticals, Inc.PMA approvalDec 3, 2004FDA
SUPARTZ FXP980044
Seikagaku Corp.PMA approvalJan 24, 2001FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Seikagaku Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records